Aclaris Therapeutics Inc (ACRS)

$1.17

-0.05

(-4.1%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Aclaris Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 1.86M → 17.57M (in $), with an average increase of 63.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -29.56M → -1.49M (in $), with an average increase of 931.8% per quarter

  • Vs IQV

    In the last 1 year, Iqvia Holdings Inc. has given 24.5% return, outperforming this stock by 110.9%

  • Vs TMO

    In the last 3 years, Thermo Fisher Scientific, Inc. has given 2.7% return, outperforming this stock by 98.1%

Performance

  • $1.15
    $1.24
    $1.17
    downward going graph

    2.14%

    Downside

    Day's Volatility :7.29%

    Upside

    5.26%

    downward going graph
  • $0.59
    $11.12
    $1.17
    downward going graph

    49.56%

    Downside

    52 Weeks Volatility :94.69%

    Upside

    89.48%

    downward going graph

Returns

PeriodAclaris Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-2.4%
2.0%
0.0%
6 Months
-73.82%
11.7%
0.0%
1 Year
-86.37%
5.8%
1.3%
3 Years
-95.32%
14.2%
-22.1%

Highlights

Market Capitalization
86.5M
Book Value
$2.22
Earnings Per Share (EPS)
-1.27
PEG Ratio
-0.13
Wall Street Target Price
1.8
Profit Margin
-283.15%
Operating Margin TTM
-134.99%
Return On Assets TTM
-32.53%
Return On Equity TTM
-49.88%
Revenue TTM
31.2M
Revenue Per Share TTM
0.45
Quarterly Revenue Growth YOY
126.6%
Gross Profit TTM
-60.0M
EBITDA
-117.6M
Diluted Eps TTM
-1.27
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.99
EPS Estimate Next Year
-0.82
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Aclaris Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
13
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.85%

Current $1.17
Target $1.80

Company Financials

FY18Y/Y Change
Revenue
10.1M
↑ 499.58%
Net Income
-132.7M
↑ 93.71%
Net Profit Margin
-1.3K%
↑ 2756.07%
FY19Y/Y Change
Revenue
4.2M
↓ 58.11%
Net Income
-142.9M
↑ 7.62%
Net Profit Margin
-3.4K%
↓ 2064.06%
FY20Y/Y Change
Revenue
6.5M
↑ 53.35%
Net Income
-51.2M
↓ 64.19%
Net Profit Margin
-789.17%
↑ 2590.3%
FY21Y/Y Change
Revenue
6.8M
↑ 4.3%
Net Income
-114.3M
↑ 123.41%
Net Profit Margin
-1.7K%
↓ 901.13%
FY22Y/Y Change
Revenue
29.8M
↑ 340.05%
Net Income
-88.7M
↓ 22.42%
Net Profit Margin
-298.0%
↑ 1392.3%
FY23Y/Y Change
Revenue
31.2M
↑ 5.03%
Net Income
-88.5M
↓ 0.2%
Net Profit Margin
-283.15%
↑ 14.85%
Q3 FY22Q/Q Change
Revenue
19.0M
↑ 1144.63%
Net Income
-21.2M
↑ 27.35%
Net Profit Margin
-111.63%
↑ 979.34%
Q4 FY22Q/Q Change
Revenue
7.8M
↓ 59.23%
Net Income
-33.3M
↑ 56.81%
Net Profit Margin
-429.4%
↓ 317.77%
Q1 FY23Q/Q Change
Revenue
2.5M
↓ 67.39%
Net Income
-26.4M
↓ 20.69%
Net Profit Margin
-1.0K%
↓ 614.98%
Q2 FY23Q/Q Change
Revenue
1.9M
↓ 26.07%
Net Income
-29.6M
↑ 12.0%
Net Profit Margin
-1.6K%
↓ 537.7%
Q3 FY23Q/Q Change
Revenue
9.3M
↑ 396.63%
Net Income
-29.3M
↓ 1.04%
Net Profit Margin
-315.24%
↑ 1266.84%
Q4 FY23Q/Q Change
Revenue
17.6M
↑ 89.29%
Net Income
-1.5M
↓ 94.9%
Net Profit Margin
-8.49%
↑ 306.75%
FY18Y/Y Change
Total Assets
275.6M
↑ 13.16%
Total Liabilities
60.4M
↑ 231.24%
FY19Y/Y Change
Total Assets
98.3M
↓ 64.33%
Total Liabilities
28.4M
↓ 53.04%
FY20Y/Y Change
Total Assets
70.8M
↓ 27.99%
Total Liabilities
33.1M
↑ 16.73%
FY21Y/Y Change
Total Assets
251.2M
↑ 254.9%
Total Liabilities
53.9M
↑ 62.58%
FY22Y/Y Change
Total Assets
254.6M
↑ 1.35%
Total Liabilities
57.0M
↑ 5.76%
FY23Y/Y Change
Total Assets
197.4M
↓ 22.46%
Total Liabilities
40.2M
↓ 29.4%
Q3 FY22Q/Q Change
Total Assets
267.6M
↓ 3.72%
Total Liabilities
47.8M
↑ 13.19%
Q4 FY22Q/Q Change
Total Assets
254.6M
↓ 4.87%
Total Liabilities
57.0M
↑ 19.21%
Q1 FY23Q/Q Change
Total Assets
229.7M
↓ 9.78%
Total Liabilities
52.9M
↓ 7.16%
Q2 FY23Q/Q Change
Total Assets
235.6M
↑ 2.59%
Total Liabilities
55.9M
↑ 5.68%
Q3 FY23Q/Q Change
Total Assets
218.4M
↓ 7.34%
Total Liabilities
62.0M
↑ 10.95%
Q4 FY23Q/Q Change
Total Assets
197.4M
↓ 9.59%
Total Liabilities
40.2M
↓ 35.14%
FY18Y/Y Change
Operating Cash Flow
-100.8M
↑ 84.42%
Investing Cash Flow
9.4M
↓ 116.82%
Financing Cash Flow
128.3M
↑ 27.77%
FY19Y/Y Change
Operating Cash Flow
-96.4M
↓ 4.33%
Investing Cash Flow
105.7M
↑ 1028.21%
Financing Cash Flow
-30.3M
↓ 123.64%
FY20Y/Y Change
Operating Cash Flow
-38.6M
↓ 59.94%
Investing Cash Flow
6.4M
↓ 93.96%
Financing Cash Flow
18.4M
↓ 160.6%
FY21Y/Y Change
Operating Cash Flow
-52.1M
↑ 34.95%
Investing Cash Flow
-167.6M
↓ 2724.58%
Financing Cash Flow
225.1M
↑ 1124.97%
FY22Y/Y Change
Operating Cash Flow
-67.6M
↑ 29.6%
Investing Cash Flow
12.6M
↓ 107.53%
Financing Cash Flow
72.9M
↓ 67.62%
Q3 FY22Q/Q Change
Operating Cash Flow
-7.8M
↓ 60.25%
Investing Cash Flow
1.2M
↓ 105.73%
Financing Cash Flow
-11.0K
↓ 100.02%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.1M
↑ 144.53%
Investing Cash Flow
2.7M
↑ 122.02%
Financing Cash Flow
37.0K
↓ 436.36%
Q1 FY23Q/Q Change
Operating Cash Flow
-26.4M
↑ 37.87%
Investing Cash Flow
25.8M
↑ 854.77%
Financing Cash Flow
26.7M
↑ 72181.08%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.7M
↓ 21.63%
Investing Cash Flow
-19.7M
↓ 176.22%
Financing Cash Flow
26.7M
↑ 0.0%
Q3 FY23Q/Q Change
Operating Cash Flow
-24.6M
↑ 18.9%
Investing Cash Flow
32.5M
↓ 265.47%
Financing Cash Flow
-87.0K
↓ 100.33%

Technicals Summary

Sell

Neutral

Buy

Aclaris Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
5.17%
-73.82%
-86.37%
-95.32%
-82.14%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-6.78%
14.63%
-1.95%
-11.57%
119.88%
Agilent Technologies Inc.
Agilent Technologies Inc.
-4.37%
34.62%
6.77%
1.35%
81.44%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
0.18%
25.39%
0.05%
16.3%
119.68%
Danaher Corp.
Danaher Corp.
2.14%
28.59%
-0.49%
-1.93%
95.75%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-4.12%
27.82%
17.55%
2.23%
75.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
NA
NA
-0.13
-0.99
-0.5
-0.33
NA
2.22
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.62
47.62
4.75
11.13
0.81
0.23
NA
17.88
Agilent Technologies Inc.
Agilent Technologies Inc.
32.04
32.04
2.7
5.5
0.21
0.08
0.01
21.12
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.47
35.47
2.81
21.55
0.13
0.05
0.0
120.87
Danaher Corp.
Danaher Corp.
41.86
41.86
3.13
7.62
0.08
0.04
0.0
72.36
Iqvia Holdings Inc.
Iqvia Holdings Inc.
32.69
32.69
1.33
11.11
0.23
0.05
NA
33.67
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aclaris Therapeutics Inc
Aclaris Therapeutics Inc
Buy
$86.5M
-82.14%
NA
-283.15%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.8B
119.88%
47.62
23.08%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.2B
81.44%
32.04
18.35%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$209.3B
119.68%
35.47
13.99%
Danaher Corp.
Danaher Corp.
Buy
$174.8B
95.75%
41.86
19.94%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$43.4B
75.73%
32.69
9.06%

Institutional Holdings

  • Bvf Inc

    9.96%

  • BlackRock Inc

    8.33%

  • Vanguard Group Inc

    6.66%

  • Bain Capital Life Sciences Investors, LLC

    4.93%

  • Millennium Management LLC

    4.91%

  • Citadel Advisors Llc

    4.73%

Corporate Announcements

  • Aclaris Therapeutics Inc Earnings

    Aclaris Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

Organization
Aclaris Therapeutics Inc
Employees
86
CEO
Dr. Neal S. Walker D.O., M.D.
Industry
Health Technology

Discover More

FAQs